Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Thoracic 4Genitourinary 2Gastrointestinal 2Dermatologic 2Gynecologic 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Carcinoma, Transitional Cell 3Waldenstrom Macroglobulinemia 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2

Interventions

pembrolizumab 28Nivolumab 14Ipilimumab 7Cyclophosphamide 7spartalizumab 6atezolizumab 4Interleukin-2 4fludarabine 3durvalumab 3cemiplimab 3avelumab 3aldesleukin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Immune Checkpoint Inhibitors 3Docetaxel 3obinutuzumab 2epacadostat 2budigalimab 2bempegaldesleukin 2Pemetrexed 2Paclitaxel 2Leucovorin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vocimagene amiretrorepvec 1venetoclax 1utomilumab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Pemetrexed × Dermatologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡